---
title: "Genetic Engineering and Biotechnology"
book: "University Biology — Year 3"
subject: biology
language: en
chapter: 6
exercises: 12
source: https://one-course.com/books/biology/5/en/chapter/6-genetic-engineering-and-biotechnology
---

# Chapter 6 — Genetic Engineering and Biotechnology

Until 1982 every diabetic in the world was kept alive by insulin extracted from the pancreases of pigs and cattle — some eight thousand kilograms of glands for a kilogram of hormone — and a fraction of patients reacted against the foreign protein. That year the first drug made by a genetically engineered organism reached the market: human insulin, synthesised by *Escherichia coli* carrying the human gene on a [plasmid](#def-b3-genetic-engineering-tools). The tools that made it possible had been assembled over the preceding decade — enzymes that cut DNA at chosen sequences, enzymes that join the pieces, [plasmids](#def-b3-genetic-engineering-tools) that carry them into a cell and copy them there — and were joined in the following ones by the [polymerase chain reaction](#def-b3-genetic-engineering-pcr), by the injection of genes into embryos, and, since 2012, by a bacterial immune system turned into a programmable pair of scissors that can rewrite one letter of a genome in a living cell. This chapter is about those tools, the arithmetic that governs their use, and what has been built with them, from a glowing mouse to a cure for sickle-cell disease.

## 6.1 Cutting, joining and copying DNA

**Definition 6.1 (Restriction enzymes, ligase and vectors).**

A type II *restriction enzyme* is a bacterial endonuclease that cuts double-stranded DNA at a specific sequence of $4\text{ to }8$ base pairs, usually a palindrome: EcoRI cuts G$^{\downarrow}$AATTC, leaving four-base single-stranded overhangs (*sticky ends*) complementary to any other EcoRI end; other enzymes leave *blunt ends*. *DNA ligase* seals two fragments whose ends fit. A *vector* is a DNA molecule that replicates in a host and can carry an inserted fragment: a *plasmid* of a few kilobases with an origin of replication, a *selectable marker* (an antibiotic resistance gene, so that only cells that took up the plasmid grow on the antibiotic) and a cluster of unique restriction sites for the insert; bacteriophage $\lambda$, cosmids, and bacterial or yeast artificial chromosomes for inserts of $20\text{ to }1000\,\mathrm{kb}$. DNA enters a bacterium by *transformation*, after a chemical or electrical shock that makes the membrane transiently permeable, with an efficiency of $10^{6}$ to $10^{9}$ transformants per microgram of plasmid. A *recombinant* molecule is one that joins DNA from two sources.

**Evidence.** Cohen, Chang, Boyer and Helling (1973) cut the [plasmid](#def-b3-genetic-engineering-tools) pSC101 and a second [plasmid](#def-b3-genetic-engineering-tools) carrying a different resistance gene with EcoRI, mixed and ligated the fragments, transformed *E. coli*, and recovered colonies resistant to both antibiotics carrying a single [plasmid](#def-b3-genetic-engineering-tools) made of both — the first recombinant DNA to replicate in a cell. The next year they inserted ribosomal RNA genes of a toad into pSC101 and showed that the frog DNA was replicated, and transcribed, in the bacterium: genes cross the boundary between kingdoms unchanged, and a bacterium will copy whatever DNA it is given. ∎

![A cloning vector and its chemistry. The plasmid carries an origin, a selectable marker and a unique restriction site into which a fragment cut with the same enzyme is ligated; sticky ends make any two fragments cut by the same enzyme compatible.](https://one-course.com/images/onecourse/chapters/biology-5/b3-genetic-engineering/fig-bf782fa87786.svg)

*A cloning [vector](#def-b3-genetic-engineering-tools) and its chemistry. The [plasmid](#def-b3-genetic-engineering-tools) carries an origin, a [selectable marker](#def-b3-genetic-engineering-tools) and a unique restriction site into which a fragment cut with the same enzyme is ligated; [sticky ends](#def-b3-genetic-engineering-tools) make any two fragments cut by the same enzyme compatible.*

**Method 6.2 (Cloning a gene).**

(1) Obtain the insert: cut genomic DNA with a [restriction enzyme](#def-b3-genetic-engineering-tools), or copy messenger RNA into complementary DNA (cDNA, which lacks introns and so can be expressed in bacteria), or amplify the gene by PCR with [primers](#def-b3-genetic-engineering-pcr) carrying restriction sites. (2) Cut [vector](#def-b3-genetic-engineering-tools) and insert with the same enzyme(s) — two different enzymes force the insert’s orientation — and ligate. (3) Transform bacteria and plate on the antibiotic: only cells with a [plasmid](#def-b3-genetic-engineering-tools) grow. (4) Distinguish [plasmids](#def-b3-genetic-engineering-tools) with an insert from those that closed on themselves: a marker gene interrupted by the cloning site (*lacZ*: white colonies have an insert, blue do not). (5) Screen the colonies for the desired insert: by hybridisation with a labelled probe, by PCR, or by restriction digestion and gel electrophoresis. (6) Sequence the insert. A *library* is the collection of clones from a whole genome or transcriptome, from which any gene can be fished by the same screen.

![An agarose gel under ultraviolet light: DNA fragments migrate toward the anode at a speed that falls with their length, so each band is a population of molecules of one size, compared with the ladder of known sizes in the outer lanes.](https://one-course.com/images/onecourse/chapters/biology-5/b3-genetic-engineering/img-e101172496f1.jpg)

*An agarose gel under ultraviolet light: DNA fragments migrate toward the anode at a speed that falls with their length, so each band is a population of molecules of one size, compared with the ladder of known sizes in the outer lanes.*

**Definition 6.3 (The polymerase chain reaction).**

The *polymerase chain reaction* (PCR) amplifies a chosen stretch of DNA between two *primers* — synthetic oligonucleotides of about twenty bases complementary to the two strands at the ends of the target — through cycles of three temperatures: $95\,{}^{\circ}\mathrm{C}$ to separate the strands, $50\text{ to }65\,{}^{\circ}\mathrm{C}$ for the primers to anneal, $72\,{}^{\circ}\mathrm{C}$ for a heat-stable polymerase (Taq, from the hot-spring bacterium *Thermus aquaticus*) to extend them. Each cycle doubles the number of copies of the segment between the primers, so thirty cycles turn a single molecule into a billion. *Reverse transcription PCR* first copies RNA into DNA and so measures transcripts or RNA viruses; *quantitative PCR* (qPCR) follows the amplification in real time with a fluorescent dye and reads the starting quantity from the cycle at which the signal crosses a threshold.

**Theorem 6.4 (The arithmetic of amplification).**

With efficiency $E$ per cycle ($E = 1$ for perfect doubling), $N_{0}$ starting copies become

$$
N_{n} = N_{0}\,(1 + E)^{n}
$$

after $n$ cycles. If the fluorescence crosses a fixed threshold when the copy number reaches $N_{T}$, the *[threshold cycle](#thm-b3-genetic-engineering-pcr)* is

$$
C_{T} = \frac{\log N_{T} - \log N_{0}}{\log(1 + E)},
$$

a straight line in $\log N_{0}$ with slope $-1/\log(1+E)$: for $E = 1$, each tenfold increase in the starting quantity lowers $C_{T}$ by $\log_{2} 10 = 3.32$ cycles, and two samples with [threshold cycles](#thm-b3-genetic-engineering-pcr) differing by $\Delta C_{T}$ differ in starting copies by the factor $(1 + E)^{\Delta C_{T}}$.

**Proof.** Each cycle multiplies the copy number by $1 + E$, so $N_{n}$ is a geometric sequence. Setting $N_{n} = N_{T}$ and solving for $n$ gives $C_{T}$; the slope is the coefficient of $\log N_{0}$. For two samples, $C_{T,1} - C_{T,2} = (\log N_{0,2} - \log N_{0,1})/\log(1+E)$, whence $N_{0,2}/N_{0,1} = (1+E)^{\Delta C_{T}}$. ∎

**Example 6.5 (Reading a qPCR plate).**

A viral RNA test crosses the threshold at cycle $22$ for one patient and cycle $32$ for another; with $E \approx 1$ the first carries $2^{10}
\approx 1000$ times more virus. A sample of ten copies crosses at about cycle $37$ when the threshold is $10^{12}$ copies ($\log_{2} 10^{11} =
36.5$); a run of $40$ cycles therefore detects a few molecules, and a single contaminating molecule of a previous amplicon does too, which is why laboratories separate the rooms where PCR is set up from those where products are handled.

![Amplification curves for N_0 = 107 (blue), 104 (red) and 10 copies (green), E = 1, with the plateau that reagents impose. A thousandfold difference in N_0 shifts the threshold cycle by 10; the plateaus are all alike, which is why the end product tells nothing about the start.](https://one-course.com/images/onecourse/chapters/biology-5/b3-genetic-engineering/fig-03c365f412f4.svg)

*Amplification curves for $N_{0} = 10^{7}$ (blue), $10^{4}$ (red) and $10$ copies (green), $E = 1$, with the plateau that reagents impose. A thousandfold difference in $N_{0}$ shifts the [threshold cycle](#thm-b3-genetic-engineering-pcr) by $10$; the plateaus are all alike, which is why the end product tells nothing about the start.*

## 6.2 Making proteins

**Definition 6.6 (Expression systems).**

An *expression [vector](#def-b3-genetic-engineering-tools)* places the cloned coding sequence under a strong, controllable promoter of the host (the *lac* or T7 promoter in *E. coli*, induced by a sugar analogue), with a ribosome-binding site, a terminator, and often a *tag* — six histidines, a small protein — fused to the product for purification on a column. Bacteria make grams per litre of a simple protein (insulin, growth hormone, enzymes) but cannot glycosylate or fold complex mammalian proteins; yeast adds sugars of its own kind; insect and mammalian cells (Chinese hamster ovary cells are the industry’s standard) make antibodies and clotting factors folded and glycosylated as in a human. A *monoclonal antibody* is made by a *hybridoma* — an antibody-producing B cell fused to an immortal myeloma cell (Köhler and Milstein, 1975) — or, now, by cloning the antibody genes into a mammalian expression line, where the mouse framework can be replaced by human sequence to avoid immune rejection ([Chapter 16](https://one-course.com/books/biology/5/en/chapter/16-adaptive-immunity-and-vaccination#ch-b3-adaptive-immunity)).

**Example 6.7 (Insulin).**

Human insulin is two chains, A (21 residues) and B (30), joined by disulfide bonds, cut in the $\beta$ cell from a single proinsulin precursor. The first process expressed the two chains separately in *E. coli*, each fused to $\beta$-galactosidase, cleaved them off chemically and joined them in vitro; later processes express proinsulin and cleave it with the enzymes the pancreas uses. Since 1996 the sequence itself has been altered: swapping or adding a residue or two gives analogues that dissociate faster (for a meal) or precipitate at the injection site and release over a day. A protein that took eight tonnes of glands per kilogram is now made in a fermenter, identical to the human one or better than it.

## 6.3 Transgenic organisms

**Definition 6.8 (Transgenesis and gene targeting).**

A *transgenic* organism carries a gene introduced into its germ line, so that every cell has it and it is inherited. In mice the classical route is *microinjection* of the DNA into one pronucleus of a fertilised egg (Gordon and Ruddle, 1980), which integrates at a random site in a fraction of embryos; Palmiter and Brinster (1982) made mice twice normal size by injecting the rat growth-hormone gene behind a metallothionein promoter. *Gene targeting* replaces or disrupts a chosen gene instead: a construct with long arms homologous to the target is introduced into *embryonic stem cells*, the rare cells in which [homologous recombination](https://one-course.com/books/biology/5/en/chapter/3-genome-stability-dna-damage-repair-and-recombination#def-b3-dna-repair-dsb) has put it in the right place are selected and injected into a blastocyst, and the chimaeric mouse that results transmits the altered gene (Capecchi, Smithies and Evans, 1980s). A *knockout* lacks the gene; a *knock-in* carries a modified version; a *conditional* allele, flanked by loxP sites, is deleted only where and when Cre is expressed ([Chapter 3](https://one-course.com/books/biology/5/en/chapter/3-genome-stability-dna-damage-repair-and-recombination#ch-b3-dna-repair)). Some ten thousand mouse genes have been knocked out, and for most the phenotype was the first indication of what the gene does.

![Left: a fertilised mouse egg held by suction while a glass needle injects DNA into one pronucleus. Right: a transgenic mouse expressing the green fluorescent protein of a jellyfish in every cell, beside an ordinary littermate, under ultraviolet light.](https://one-course.com/images/onecourse/chapters/biology-5/b3-genetic-engineering/img-7b02f90d1d34.jpg)

![Left: a fertilised mouse egg held by suction while a glass needle injects DNA into one pronucleus. Right: a transgenic mouse expressing the green fluorescent protein of a jellyfish in every cell, beside an ordinary littermate, under ultraviolet light.](https://one-course.com/images/onecourse/chapters/biology-5/b3-genetic-engineering/img-52ff6fa221af.jpg)

*Left: a fertilised mouse egg held by suction while a glass needle injects DNA into one pronucleus. Right: a [transgenic](#def-b3-genetic-engineering-transgenic) mouse expressing the green fluorescent protein of a jellyfish in every cell, beside an ordinary littermate, under ultraviolet light.*

**Definition 6.9 (Transgenic plants).**

Plants are transformed by *Agrobacterium tumefaciens*, a soil bacterium that naturally inserts a segment of its tumour-inducing [plasmid](#def-b3-genetic-engineering-tools), the *T-DNA*, into the genome of a wounded plant to make it grow a gall and feed the bacterium. Replacing the T-DNA’s own genes with any gene of choice, between the border sequences the bacterium recognises, turns the pathogen into a [vector](#def-b3-genetic-engineering-tools); the transformed cells are selected and regenerated into whole plants, which every plant cell can do. Species the bacterium does not infect (the cereals, for long) are transformed by shooting DNA-coated gold particles into tissue. *Genetically modified crops* grown at scale carry a bacterial toxin gene (*Bt*) against insect larvae, or a bacterial enzyme conferring tolerance to a herbicide, or both; *Golden Rice* carries two genes of the carotenoid pathway (a plant phytoene synthase and a bacterial desaturase) so that its endosperm makes $\beta$-carotene, the precursor of vitamin A, whose deficiency blinds and kills several hundred thousand children a year.

![Ordinary and Golden Rice. The yellow grain makes -carotene in its endosperm from two added genes of the carotenoid pathway. Right: the two rices compared at the International Rice Research Institute (IRRI, CC BY 2.0).](https://one-course.com/images/onecourse/chapters/biology-5/b3-genetic-engineering/img-40477cf07d8c.jpg)

![Ordinary and Golden Rice. The yellow grain makes -carotene in its endosperm from two added genes of the carotenoid pathway. Right: the two rices compared at the International Rice Research Institute (IRRI, CC BY 2.0).](https://one-course.com/images/onecourse/chapters/biology-5/b3-genetic-engineering/img-31d4173224b2.jpg)

*Ordinary and Golden Rice. The yellow grain makes $\beta$-carotene in its endosperm from two added genes of the carotenoid pathway. Right: the two rices compared at the International Rice Research Institute (IRRI, CC BY 2.0).*

**Remark 6.10 (The debate).**

Thirty years of cultivation on hundreds of millions of hectares, and every systematic review by scientific academies, have found no health effect of approved [transgenic](#def-b3-genetic-engineering-transgenic) crops that differs from their conventional counterparts; the transgene is one more gene among forty thousand, and the protein it makes is tested as any food additive is. The real questions are ecological and economic: the spread of resistance in pests and weeds under uniform selection, gene flow into wild relatives, the concentration of the seed market, and who benefits. They are the questions that any powerful agricultural technology raises, and the answers depend on the trait and the setting, not on the method by which the gene was moved.

## 6.4 Editing genomes

**Definition 6.11 (CRISPR–Cas9).**

Bacteria store fragments of the genomes of phages that have infected their ancestors in an array of repeats (*CRISPR*), transcribe them into short guide RNAs, and use them to direct a nuclease to cut any matching DNA that enters the cell: an adaptive immune system with a genetic memory. In *Streptococcus pyogenes* the nuclease is the single protein *Cas9*, which binds a guide RNA and a second small RNA, searches DNA for a three-base *protospacer-adjacent [motif](https://one-course.com/books/biology/5/en/chapter/5-bioinformatics-and-sequence-analysis#def-b3-bioinformatics-motif)* (PAM, 5$'$-NGG), unwinds the adjacent DNA, and, if the twenty bases next to the PAM pair with the guide, cuts both strands three bases from the PAM. Jinek, Charpentier, Doudna and colleagues (2012) fused the two RNAs into one *single-guide RNA* and showed that Cas9 with a guide of any chosen sequence cuts DNA at that sequence in a test tube; within a year the pair had been shown to work in human, mouse, zebrafish, plant and yeast cells. *Genome editing* is what the cell does with the cut: end joining leaves a small insertion or deletion that disrupts the gene (a [knockout](#def-b3-genetic-engineering-transgenic) in one step, in any organism, in weeks), and [homologous recombination](https://one-course.com/books/biology/5/en/chapter/3-genome-stability-dna-damage-repair-and-recombination#def-b3-dna-repair-dsb) with a supplied template writes in a chosen sequence.

![Cas9 and its guide. The protein binds a PAM, unwinds the DNA next to it, and cuts if the twenty bases pair with the guide RNA. The break is repaired either by end joining, which disrupts the gene, or by recombination with a template, which rewrites it.](https://one-course.com/images/onecourse/chapters/biology-5/b3-genetic-engineering/fig-36c6dd2b0401.svg)

*[Cas9](#def-b3-genetic-engineering-crispr) and its guide. The protein binds a [PAM](#def-b3-genetic-engineering-crispr), unwinds the DNA next to it, and cuts if the twenty bases pair with the [guide RNA](#def-b3-genetic-engineering-crispr). The break is repaired either by end joining, which disrupts the gene, or by recombination with a template, which rewrites it.*

**Proposition 6.12 (Editing without a break).**

Cutting both strands is the crudest edit: the outcome of end joining is random, and a break elsewhere — an *off-target* site differing from the guide at a few positions, which [Cas9](#def-b3-genetic-engineering-crispr) tolerates — is a mutation nobody asked for. A [Cas9](#def-b3-genetic-engineering-crispr) with one nuclease domain inactivated nicks a single strand; with both inactivated it merely binds, and can carry other enzymes to a sequence. *[Base editors](#prop-b3-genetic-engineering-editors)* fuse a nicking [Cas9](#def-b3-genetic-engineering-crispr) to a deaminase that converts C to U (read as T) or A to I (read as G) in the unwound strand, changing one base without a break and without a template; *[prime editors](#prop-b3-genetic-engineering-editors)* carry a reverse transcriptase and a guide extended with the desired sequence, and copy that sequence into the nicked strand, allowing any substitution and small insertions or deletions. Off-target activity is reduced by engineered high-fidelity [Cas9](#def-b3-genetic-engineering-crispr) variants, by delivering the enzyme briefly as protein rather than as a gene, and by choosing guides whose nearest genomic relatives differ at several positions; it is measured by sequencing the sites predicted, and by unbiased methods that catch every break in the genome.

**Example 6.13 (A cure).**

Sickle-cell disease is a single base change in $\beta$-globin. Fetal haemoglobin, made from $\gamma$-globin, would substitute, but the $\gamma$ genes are switched off after birth by the repressor BCL11A. The first approved [CRISPR](#def-b3-genetic-engineering-crispr) therapy (2023) takes the patient’s own blood stem cells, cuts the erythroid enhancer of *BCL11A* with [Cas9](#def-b3-genetic-engineering-crispr) so that end joining disables it in most cells, and returns the cells after the patient’s marrow has been cleared: the red cells they make are rich in fetal haemoglobin, do not sickle, and the crises stop. The edit is somatic — the germ line is untouched and the change is not inherited — and it uses the “crude” outcome, disruption, where disruption is what is wanted.

**Theorem 6.14 (Super-Mendelian spread of a gene drive).**

A *[gene drive](#thm-b3-genetic-engineering-drive)* is a construct encoding [Cas9](#def-b3-genetic-engineering-crispr) and a guide that cuts the wild-type allele at its own locus in a heterozygote; repair by recombination copies the drive into the cut chromosome, so that a fraction $c$ of the heterozygote’s gametes carry the drive instead of the Mendelian half. If the drive has frequency $p$ in a large, randomly mating population and no fitness cost, its frequency in the next generation is

$$
p' = p + c\,p\,(1 - p),
$$

so that it spreads from rarity at a rate proportional to $c$, and reaches half the population in about $\ln(1/p_{0})/\ln(1 + c)$ generations from an initial frequency $p_{0}$.

**Proof.** Random mating gives homozygotes for the drive at frequency $p^{2}$, heterozygotes at $2p(1-p)$, wild-type homozygotes at $(1-p)^{2}$. The homozygotes transmit the drive to all their gametes, the heterozygotes to a fraction $(1 + c)/2$ (half by Mendel, plus $c$ times the wild-type half converted), the wild-type to none. Hence $p' = p^{2} + 2p(1-p)(1+c)/2
= p^{2} + p(1-p) + c\,p(1-p) = p + c\,p(1-p)$. For small $p$ this is $p' \approx (1+c)p$, geometric growth with ratio $1 + c$, which reaches $1/2$ from $p_{0}$ after about $\ln(1/2p_{0})/\ln(1+c)$ generations; the logistic term slows it only near the end. ∎

![A gene drive released at one percent, with conversion efficiency 0.9 or 0.5 and no fitness cost. A Mendelian allele with no advantage would stay at one percent; the drive takes over in ten or twenty generations.](https://one-course.com/images/onecourse/chapters/biology-5/b3-genetic-engineering/fig-1ef33a8072e2.svg)

*A [gene drive](#thm-b3-genetic-engineering-drive) released at one percent, with conversion efficiency $0.9$ or $0.5$ and no fitness cost. A Mendelian allele with no advantage would stay at one percent; the drive takes over in ten or twenty generations.*

**Remark 6.15 (What may be edited).**

Editing the somatic cells of a consenting patient is medicine, judged like any treatment by its risks and benefits. Editing the germ line — an embryo, whose every descendant would carry the change — is different in kind: the person affected cannot consent, the change is inherited, and the technique’s off-target and mosaic outcomes are not yet controlled; after a Chinese scientist announced in 2018 that he had done it in twins, the scientific academies of most countries called for a moratorium and several states made it a crime. A [gene drive](#thm-b3-genetic-engineering-drive) released into a wild population is a decision taken for everyone downstream, which is why the field’s own proposals for eliminating malaria mosquitoes couple the drives to fail-safes — reversal drives, self-limiting designs — and to public consent in the countries concerned.

## 6.5 Exercises

**Exercise 6.1 ★.**

List the three components a cloning [plasmid](#def-b3-genetic-engineering-tools) must have and explain the purpose of each.

**Solution of Exercise 6.1.**

An origin of replication, so that the host copies the [plasmid](#def-b3-genetic-engineering-tools) and passes it to daughter cells; a [selectable marker](#def-b3-genetic-engineering-tools), usually antibiotic resistance, so that only cells carrying the [plasmid](#def-b3-genetic-engineering-tools) grow; and a unique restriction site (or cluster of sites) at which the insert is ligated without cutting the [plasmid](#def-b3-genetic-engineering-tools) elsewhere.

**Exercise 6.2 ★.**

EcoRI recognises GAATTC. How often does the site occur, on average, in random DNA, and how many fragments does it make of the $4.6\,\mathrm{Mb}$ *E. coli* genome? Why is the real number somewhat different?

**Solution of Exercise 6.2.**

A given six-base sequence occurs once every $4^{6} = 4096$ bp in random DNA: about $4.6\times 10^{6}/4096 \approx 1100$ fragments averaging $4.1\,\mathrm{kb}$. Real genomes are not random — base composition, codon usage and the avoidance of some sequences shift the count (the actual number of EcoRI sites in *E. coli* is several hundred).

**Exercise 6.3 ★.**

State the three temperature steps of a PCR cycle and what happens at each. Why must the polymerase be heat-stable?

**Solution of Exercise 6.3.**

Denaturation at $95\,{}^{\circ}\mathrm{C}$ separates the strands; annealing at $50\text{ to }65\,{}^{\circ}\mathrm{C}$ lets the [primers](#def-b3-genetic-engineering-pcr) pair with their sites; extension at $72\,{}^{\circ}\mathrm{C}$ lets the polymerase copy from each [primer](#def-b3-genetic-engineering-pcr). An ordinary polymerase would be destroyed at $95\,{}^{\circ}\mathrm{C}$ in the first cycle and would have to be added afresh thirty times; Taq survives all the cycles.

**Exercise 6.4 ★.**

What does [Cas9](#def-b3-genetic-engineering-crispr) need in order to cut a given sequence, and what two outcomes can follow the cut?

**Solution of Exercise 6.4.**

A [guide RNA](#def-b3-genetic-engineering-crispr) whose twenty bases match the target, and a [PAM](#def-b3-genetic-engineering-crispr) (NGG) immediately 3$'$ of the target on the non-target strand. After the [double-strand break](https://one-course.com/books/biology/5/en/chapter/3-genome-stability-dna-damage-repair-and-recombination#def-b3-dna-repair-lesions): end joining, which leaves a small insertion or deletion and usually destroys the gene’s reading frame; or [homologous recombination](https://one-course.com/books/biology/5/en/chapter/3-genome-stability-dna-damage-repair-and-recombination#def-b3-dna-repair-dsb) with a template carrying the desired sequence, which writes it in.

**Exercise 6.5 ★★.**

A PCR runs $35$ cycles at efficiency $E = 0.9$ from $50$ copies. How many copies result? A qPCR of two samples gives $C_{T} = 18.2$ and $25.5$; with $E = 0.95$, what is the ratio of their starting quantities?

**Solution of Exercise 6.5.**

$50\times 1.9^{35} = 50\times 5.7\times 10^{9} \approx 3\times 10^{11}$ copies. $\Delta C_{T} = 7.3$; ratio $1.95^{7.3} = e^{7.3\ln 1.95}
\approx 130$: the first sample had about $130$ times more template.

**Exercise 6.6 ★★.**

Why is a cDNA library, and not a genomic library, used to express a human protein in bacteria? Name two other obstacles to making a human protein in *E. coli* and say how each is overcome.

**Solution of Exercise 6.6.**

Bacteria cannot splice: a genomic copy with introns would be transcribed into an unusable message, so the intron-free cDNA, copied from the mature mRNA, is used. Other obstacles: the human promoter is not recognised by bacterial polymerase (supply a bacterial promoter and ribosome-binding site); human codon usage differs (synthesise the gene with the host’s preferred codons); the protein may not fold or may aggregate (lower the temperature, fuse to a soluble partner, or refold from inclusion bodies); glycosylation is absent (use yeast or mammalian cells if it matters); disulfides need the oxidising periplasm.

**Exercise 6.7 ★★.**

A [knockout](#def-b3-genetic-engineering-transgenic) mouse is made by [gene targeting](#def-b3-genetic-engineering-transgenic) in [embryonic stem cells](#def-b3-genetic-engineering-transgenic). Explain why the first mouse born is a chimaera, why one must breed it, and what fraction of the grandchildren of a chimaera whose germ line is half targeted are homozygous [knockouts](#def-b3-genetic-engineering-transgenic) if heterozygous grandparents are intercrossed.

**Solution of Exercise 6.7.**

The targeted stem cells are injected into a host blastocyst and mix with its own cells, so the mouse is built from two genotypes — a chimaera — and only if some of its germ cells derive from the targeted cells does it transmit the allele. Breeding the chimaera to a wild-type mouse gives heterozygotes (from half its gametes if half the germ line is targeted); intercrossing heterozygotes gives one quarter homozygous [knockouts](#def-b3-genetic-engineering-transgenic).

**Exercise 6.8 ★★.**

A [guide RNA](#def-b3-genetic-engineering-crispr) of 20 bases with an NGG [PAM](#def-b3-genetic-engineering-crispr) is chosen. How many sites in a $3.2\times 10^{9}$ bp genome (both strands) match the guide exactly by chance? How many match with up to two mismatches, if [Cas9](#def-b3-genetic-engineering-crispr) tolerates them? (Count sequences within two mismatches as $1 + 3\binom{20}{1} +
9\binom{20}{2}$.)

**Solution of Exercise 6.8.**

Exact: $6.4\times 10^{9}\times 4^{-20}\times (1/16) \approx 4\times
10^{-4}$ sites (the GG of the [PAM](#def-b3-genetic-engineering-crispr) costs a factor $16$) — none, in practice. Within two mismatches there are $1 + 60 + 1710 = 1771$ sequences: $1771\times 4\times 10^{-4} \approx 0.7$ chance sites. The real genome is not random, and a guide is checked against it directly.

**Exercise 6.9 ★★.**

Using [Theorem 6.14](#thm-b3-genetic-engineering-drive), compute the frequency of a drive with $c = 0.8$ after three generations from $p_{0} = 0.05$, and estimate the number of generations to reach $0.5$.

**Solution of Exercise 6.9.**

$p_{1} = 0.05 + 0.8\times 0.05\times 0.95 = 0.088$; $p_{2} = 0.152$; $p_{3} = 0.255$; then $0.41$, $0.60$: about five generations to pass $0.5$, against the estimate $\ln(1/(2\times 0.05))/\ln 1.8 \approx 4$.

**Exercise 6.10 ★★★.**

The sickle-cell therapy disrupts an enhancer rather than correcting the $\beta$-globin mutation. Give two reasons why disruption by end joining was chosen over correction by [homologous recombination](https://one-course.com/books/biology/5/en/chapter/3-genome-stability-dna-damage-repair-and-recombination#def-b3-dna-repair-dsb) in blood stem cells, and one drawback.

**Solution of Exercise 6.10.**

End joining acts in every cell, including quiescent stem cells in which [homologous recombination](https://one-course.com/books/biology/5/en/chapter/3-genome-stability-dna-damage-repair-and-recombination#def-b3-dna-repair-dsb), an S/G2 process, is inefficient; it needs no template to be delivered and its product — any disruption of the enhancer — does the job, whereas correction requires the exact sequence and yields a minority of cells. Also, the same edit works for every $\beta$-globin mutation, sickle or thalassaemic. Drawback: it removes a regulatory element (with whatever other roles it has), it leaves the sickle allele in place, and the mixture of indels is uncontrolled.

**Exercise 6.11 ★★★.**

A [gene drive](#thm-b3-genetic-engineering-drive) against a mosquito carries a fitness cost $s$ in homozygotes. Modify the recursion to include selection against drive homozygotes and find the condition on $c$ and $s$ for the drive to spread from rarity. Then explain why resistance alleles — end-joining products at the target that the guide no longer recognises — are the principal obstacle in practice.

**Solution of Exercise 6.11.**

With homozygote fitness $1 - s$: $p' = \bigl[p^{2}(1-s) + p(1-p)(1+c)
\bigr]/(1 - sp^{2})$. From rarity homozygotes are negligible and the drive grows as $(1+c)p$ whatever $s$; whether it goes to fixation is decided near $p = 1$, where a rare wild-type allele of frequency $q$ returns as $q' \approx q(1-c)/(1-s)$: fixation if $c > s$, an intermediate equilibrium otherwise. Resistance: each failed conversion (end joining instead of recombination) leaves an allele that the guide no longer recognises; if such alleles are fit — an in-frame indel in a non-essential region — they carry no cost while the drive does, so selection favours them and they replace the drive. The remedies are to target essential sequences where indels are lethal, and to use several guides at once.

**Exercise 6.12 ★★★.**

Argue, with the mechanisms of this chapter and of [Chapter 3](https://one-course.com/books/biology/5/en/chapter/3-genome-stability-dna-damage-repair-and-recombination#ch-b3-dna-repair), why germline editing of a human embryo cannot at present guarantee the intended outcome in every cell, and what evidence would be needed before a rational person could consider it safe.

**Solution of Exercise 6.12.**

[Cas9](#def-b3-genetic-engineering-crispr) injected into a zygote may act after the first divisions, so different cells receive different repairs — mosaicism; the repair of each break is chosen by the cell, end joining giving unpredictable indels and large deletions or loss of heterozygosity at the cut; the homologous-recombination outcome is a minority; off-target breaks occur at sites that cannot all be predicted; and the embryo can only be checked by sequencing a few biopsied cells, which cannot speak for the rest. Evidence needed: methods that edit every cell identically (before the first S phase) with efficiencies near $100\,\%$, whole-genome sequencing of every cell of edited animal embryos showing no unintended change, and long-term follow-up of edited animals over generations — none of which exists.

## 6.6 Problem: From a Gene to a Drug and a Crop

**Problem 6.1.**

Weekend problem — a gene cloned with the arithmetic of restriction sites and transformation, a virus counted by qPCR, a hormone produced by the tonne in a fermenter, a genome edited with its off-targets counted, and a gene drive timed, ending on the copies of a virus in a sample, the annual fermenter volume for the world’s insulin and the number of generations a drive needs

Data: a $1.5\,\mathrm{kb}$ gene; a six-base restriction site; a [plasmid](#def-b3-genetic-engineering-tools) of $4\,\mathrm{kb}$; transformation efficiency $2\times 10^{7}$ colonies per microgram of [plasmid](#def-b3-genetic-engineering-tools); ligation gives $10\,\%$ of [plasmids](#def-b3-genetic-engineering-tools) an insert. qPCR efficiency $E = 1$, threshold $N_{T} = 10^{12}$. Insulin: $5.8\,\mathrm{kDa}$, a patient uses $40$ units a day, one unit being $35\,\text{µ}\mathrm{g}$; $10^{7}$ patients; a fermenter yields $2\,\mathrm{g}/\mathrm{L}$ of product per batch, ten batches a year. Genome $3.2\times
10^{9}$ bp. Drive conversion $c = 0.9$, released at $p_{0} = 0.001$.

**Part I — Cloning.**

1. How often does a given six-base site occur in random DNA? What is the probability that the $1.5\,\mathrm{kb}$ gene contains no such site, so that the enzyme can be used to clone it whole?
2. If it does contain a site, how would you clone it anyway? (Two methods.)
3. $100\,\mathrm{ng}$ of ligated [plasmid](#def-b3-genetic-engineering-tools) is transformed. How many colonies, and how many carry the insert?
4. Blue–white screening is used. What fraction of colonies is white, and how many white colonies must be picked to have a $99\,\%$ chance that at least one carries the gene in the right orientation (half of the inserts)?
5. The recombinant [plasmid](#def-b3-genetic-engineering-tools) is $5.5\,\mathrm{kb}$ . A cell holds $50$ copies and divides every $30\,\mathrm{min}$ . After overnight growth ( $16\,\mathrm{h}$ ) from one cell, how many [plasmid](#def-b3-genetic-engineering-tools) molecules, and what mass of [plasmid](#def-b3-genetic-engineering-tools) DNA ( $650\,\mathrm{Da}$ per base pair)?
6. Why does the [plasmid](#def-b3-genetic-engineering-tools) need a bacterial origin but the inserted human gene need no bacterial promoter for cloning, whereas it does for expression?

**Part II — Counting a virus.**

7. A patient’s sample crosses the threshold at $C_{T} = 28$ . How many copies were in the reaction? Another at $C_{T} = 35$ ?
8. Sensitivity: how many cycles are needed to bring a single copy to the threshold?
9. The test’s cut-off is set at $C_{T} = 38$ . What number of copies does that correspond to, and why not use $45$ cycles?
10. A contaminating molecule of a previous run’s product enters a negative sample. At what cycle does it cross the threshold? What laboratory practice prevents this?
11. Reverse transcription converts $40\,\%$ of viral RNA to DNA. Correct the count of question 7 for the first sample.
12. Two samples differ by $\Delta C_{T} = 3.3$ with $E = 1$ , but the efficiency is actually $0.9$ . What fold difference does the analyst report, and what is the true one?

**Part III — Insulin by the tonne.**

13. Compute the daily insulin mass per patient and the annual world requirement for $10^{7}$ patients, in kilograms.
14. How many moles of insulin is that, and how many molecules?
15. What fermenter volume, run ten batches a year, produces it? Compare with a swimming pool of $2500\,\mathrm{m}^{3}$ .
16. Extraction from glands gave $1\,\mathrm{kg}$ of insulin per $8000\,\mathrm{kg}$ of pancreas; a pig pancreas weighs $100\,\mathrm{g}$ . How many pigs a year would the world need?
17. Why is the recombinant hormone preferred even where animal insulin is cheap? Give two reasons.
18. Insulin analogues differ from the human sequence by one or two residues. Explain why an analogue is still a drug that acts on the human receptor, and why a change of one residue can alter its dissociation time.

**Part IV — Editing and driving.**

19. How many exact matches of a 20-base guide plus NGG does the genome contain by chance (both strands: $6.4\times 10^{9}$ positions)?
20. If [Cas9](#def-b3-genetic-engineering-crispr) tolerates up to three mismatches, how many sequences are within three mismatches of the guide, and how many chance off-target sites result?
21. The edited blood stem cells are $10^{7}$ ; $80\,\%$ carry the intended disruption. How many cells carry an off-target break at a given site if it is cut in one cell in $10^{4}$ , and why is a break in a tumour-suppressor gene in a single stem cell a concern?
22. Compute the drive’s frequency after $1, 2, 3$ generations from $p_{0} = 0.001$ , and estimate the generations to $0.5$ .
23. A mosquito has ten generations a year. How many years to take over? How does a fitness cost of $20\,\%$ in homozygotes change the picture qualitatively?
24. A resistance allele arises when end joining, not recombination, repairs the cut, with probability $1 - c = 0.1$ per conversion attempt. Estimate the number of resistance alleles created in a population of $10^{6}$ heterozygotes in one generation, and explain what happens to the drive if they are fit.
25. Summarise: the copies in the first sample (question 7), the world’s annual insulin fermenter volume (question 15), and the generations for the drive to reach half the population (question 22).

**Solution of Problem 6.1.**

**1.** Once per $4096$ bp. $P(\text{no site}) = (1 - 1/4096)^{1500}
= e^{-0.37} = 0.69$. **2.** Choose an enzyme with no site in the gene; or amplify the gene by PCR with [primers](#def-b3-genetic-engineering-pcr) that carry new restriction sites at their 5$'$ ends (or use blunt or ligation-independent cloning). **3.** $0.1\,\text{µ}\mathrm{g}$ $\times 2\times 10^{7} = 2\times
10^{6}$ colonies; $10\,\%$, $2\times 10^{5}$, carry the insert. **4.** White: $10\,\%$. Half the inserts are in the right orientation, so $P(\text{none in } n \text{ whites}) = 0.5^{n} \le 0.01$ gives $n \ge 6.6$: pick seven. **5.** $32$ doublings, $2^{32} = 4.3\times 10^{9}$ cells, $2.1\times
10^{11}$ [plasmids](#def-b3-genetic-engineering-tools); each $5500\times 650 = 3.6\times 10^{6}$ Da $=
5.9\times 10^{-18}$ g: $1.3\,\text{µ}\mathrm{g}$ of [plasmid](#def-b3-genetic-engineering-tools). **6.** Cloning needs only replication, supplied by the [plasmid](#def-b3-genetic-engineering-tools)’s origin; the human promoter is not read by bacterial RNA polymerase, so for expression a bacterial promoter and ribosome-binding site must be put in front of the (intron-free) coding sequence. **7.** $N_{0} = N_{T}/2^{C_{T}}$: $10^{12}/2^{28} \approx 3700$ copies; at $C_{T} = 35$, $10^{12}/2^{35} \approx 29$ copies. **8.** $2^{n} = 10^{12}$: $n = 39.9$, forty cycles. **9.** $10^{12}/2^{38} \approx 3.6$ copies. Beyond about $40$ cycles a single contaminating molecule, or [primer](#def-b3-genetic-engineering-pcr) artefacts, reach the threshold, and a sample of fewer than one copy is meaningless. **10.** One molecule crosses at cycle $40$: a positive. Prevent it with separate rooms and equipment for setting up and for handling products, one-way workflow, negative controls in every run, and enzymatic destruction of carried-over amplicons. **11.** $3700/0.4 \approx 9000$ RNA copies. **12.** Reported $2^{3.3} \approx 10$-fold; true $1.9^{3.3} =
e^{3.3\ln 1.9} \approx 8.3$-fold. **13.** $40\times 35\,\text{µ}\mathrm{g} = 1.4\,\mathrm{mg}$ a day, $0.51\,\mathrm{g}$ a year; $\times 10^{7}$: $5100\,\mathrm{kg}$ a year. **14.** $5.1\times 10^{6}/5800 \approx 880$ mol; $5.3\times 10^{26}$ molecules. **15.** $5.1\times 10^{6}$ g $/ (20$ g/L$) = 2.6\times 10^{5}$ L $= 260\,\mathrm{m}^{3}$ — a tenth of the pool. **16.** $5100\times 8000 = 4.1\times 10^{7}$ kg of pancreas, at $0.1\,\mathrm{kg}$ each: $4\times 10^{8}$ pigs a year. **17.** The recombinant hormone is identical to the human one, so it raises no antibodies and causes no allergic reactions; it carries no animal pathogens (viruses, prions); supply does not depend on slaughter; and the sequence can be improved. **18.** The residues that touch the receptor are unchanged, so binding and signalling are those of insulin; the altered residues lie at the surface where insulin molecules associate into dimers and hexamers, and changing them changes how fast the injected depot falls apart into absorbable monomers. **19.** $6.4\times 10^{9}\times 4^{-20}/16 \approx 3.6\times
10^{-4}$: no exact chance match. **20.** $1 + 60 + 1710 + 27\times 1140 = 32\,551$ sequences; $32\,551\times 3.6\times 10^{-4} \approx 12$ chance off-target sites. **21.** $10^{7}\times 10^{-4} = 1000$ cells. A stem cell lives and divides for the patient’s lifetime; one that has lost a tumour suppressor, or acquired a translocation, can found a clone that becomes a leukaemia. **22.** $p_{1} = 0.0019$, $p_{2} = 0.0036$, $p_{3} = 0.0069$; geometric growth by $1.9$ per generation gives $\ln 500/\ln 1.9
\approx 10$; iterating the recursion, the frequency passes $0.5$ at generation $11$ ($0.45 \to 0.68$). **23.** About a year. A $20\,\%$ cost in homozygotes is less than $c = 0.9$, so the drive still goes to fixation, more slowly, while the population’s mean fitness falls — which is the purpose of a suppression drive; a cost above $c$ would stall it at an intermediate frequency. **24.** $10^{6}\times 0.1 = 10^{5}$ resistance alleles in one generation. Being uncuttable and, if fit, cost-free while the drive is costly, they are favoured and spread, and the drive is eliminated — so drives target sites where end-joining products are lethal, with several guides at once. **25.** About $3700$ copies in the first sample; some $260\,\mathrm{m}^{3}$ of fermenter a year for the world’s insulin; about $11$ generations, a mosquito year, for the drive.